Home / Companies / News / Glenmark to begin clinical trial in India to test Covid-19 drug combination

Glenmark to begin clinical trial in India to test Covid-19 drug combination

Drugmakers across the world have been rushing to develop a treatment or vaccine for the fast-spreading coronavirus, which has infected 5.5 million people globally, killing more than 345,000

Premium

Glenmark said it had received Indian regulatory approval for the trial of the combination drug candidate

2 min read Last Updated : May 26 2020 | 1:49 PM IST

Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs, favipiravir and umifenovir, as a potential Covid-19 treatment.

The study will look to enroll 158 hospitalized patients suffering from moderate Covid-19 infections in India, the company said, the Reuters reported.

Drugmakers across the world have been rushing to develop a treatment or vaccine for the fast-spreading coronavirus, which has infected 5.5 million people globally, killing more than 345,000.

In India, now among the 10 most affected nations, the death toll from Covid-19 reached 4,167 on Tuesday.

Topics : Coronavirus Glenmark Pharmaceuticals Vaccination

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in